Table 4.

Tyrosine kinase inhibitors approved by the Food and Drug Administration and European Medicines Agency for advanced radioactive iodine refractory differentiated thyroid cancer.

Drug	Target	Indication
sorafenib	RET, c-KIT, VEGFR 1-3, PDGFR, BRAF	RAI-R DTC
lenvatinib	RET, c-KIT, VEGFR 1-3, PDGFR, FGFR	RAI-R DTC
selpercatinib	RET	RAI-R DTC with RET fusion
pralsetinib	RET	RAI-R DTC with RET fusion
larotrectinib	NTRK	Advanced solid tumors with NTRK gene fusion
entrectinib	NTRK, ALK, ROS	Advanced solid tumors with NTRK gene fusion

Abbreviations: radioactive iodine refractory (RAI-R); differentiated thyroid cancer (DTC); rapidly accelerated fibrosarcoma kinase (BRAF); stem cell factor receptor (c-KIT); fibroblast growth factor receptor (FGFR); neurotrophic tyrosine receptor kinase (NTRK); platelet-derived growth factor receptor (PDGFR); rearranged during transfection receptor (RET); c-ros oncogene 1 (ROS); vascular endothelial growth factor (VEGFR); anaplastic lymphoma receptor tyrosine kinase (ALK).